An interesting point in this validation analysis was that we validated the NAT-based elastic net model against the 450 tumor-derived transcriptomes data rather than NAT-derived transcriptome data because of the sample accessibility in general clinical settings. This evidence concerns the gene BRD2 and neoplasm.